Baylor Sammons Cancer Center Joins as Clinical Trial Site for Actinium's Actimab-A Clinical Trial
Actinium Pharmaceuticals, Inc.,a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition of Baylor Charles A. Sammons Cancer Center as a clinical trial site for Actimab-A. The center joins several other clinical trial sites currently participating in the Actimab-A Phase I/II trial to potentially address the rapid mortality and unmet medical need for older patients with newly diagnosed acute myeloid leukemia (AML).
View full press release